# US 11,896,590 B2 · Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,590 B2
- Document ID: US11896590B2
- Status: Granted
- Kind: B2
- Application number: 17/175,572
- Filed: 2021-02-12
- Published: 2021-07-01
- Granted: 2024-02-13
- Earliest claimed: 2016-11-01
- Assignees: Anavex Life Sciences Corp.
- Applicants: Anavex Life Sciences Corp.
- Inventors: Christopher U. Missling
- Web page: https://patentgrep.com/patent/US11896590B2

## CPC

- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61P 25/02: for peripheral neuropathies
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.

## Claims

### Claim 1

A dosage form comprising a therapeutically effective amount of 1-(3-(4(((1R, 3S, 5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine (“AV1066”) or a pharmaceutically acceptable salt thereof,
wherein the therapeutically effective amount is to relieve or prevent pain in a subject in need thereof;
wherein the AV1066 is in the (+) form substantially absent the (−) form.

### Claim 2 (depends on 1)

The dosage form of claim 1, wherein the pain is selected from nociceptive pain, visceral pain, neuropathic pain, hyperalgesia.

### Claim 3 (depends on 1)

The dosage form of claim 1, wherein the pain comprises a fracture pain, a burn pain, an obstruction pain, a postherpetic pain, or any combination thereof.

### Claim 4 (depends on 1)

The dosage form of claim 1, wherein the dosage form comprises an oral dosage form, an inhalation dosage form, a subcutaneous form, or a parenteral dosage form.

### Claim 5 (depends on 1)

The dosage form of claim 1, wherein the dosage form is administered to the subject once, twice or three times per day.

### Claim 6 (depends on 1)

The dosage form of claim 1, wherein the dosage form is administered to the subject intermittently or continuously for 1, 2, 3 or 4 weeks.

### Claim 7 (depends on 1)

The dosage form of claim 1, wherein the dosage form is a unit dosage form comprising in a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

The dosage form of claim 1, wherein the therapeutically effective amount is from about 5 mg/kg/day to about 30 mg/kg/day.

### Claim 9 (depends on 1)

The dosage form of claim 1, wherein the subject is a human adult.

### Claim 10 (depends on 1)

The dosage form of claim 1, wherein the subject is having pain or suspect of having pain.

### Claim 11 (depends on 1)

The dosage form of claim 1, wherein the subject suffers or suspect of suffering pain conditions caused by traffic accident, hard tissue fracture, burn incident, compressing tumor mass, shingles outbreak, or trigeminal neuralgia.

### Claim 12 (depends on 1)

The dosage form of claim 1, wherein the subject has undergone or is having another analgesic treatment.

### Claim 13 (depends on 12)

The dosage form of claim 12, wherein another analgesic treatment is a NSAID treatment.

### Claim 14 (depends on 1)

The dosage form of claim 1, wherein the dosage form further comprises a second analgesic.

### Claim 15 (depends on 14)

The dosage form of claim 14, wherein the second analgesic is a NSAID.

### Claim 16 (depends on 1)

The dosage form of claim 1, wherein the dosage form further comprises a pharmaceutically acceptable organic or inorganic carrier.

### Claim 17

A pharmaceutical composition comprising a therapeutically effective amount of 1-(3-(4(((1R, 3S, 5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine (“AV1066”) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier,
wherein the therapeutically effective amount is to relieve or prevent pain in a subject in need thereof;
wherein the AV1066 is in the (+) form substantially absent the (−) form.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the pain comprises nociceptive pain, visceral pain, neuropathic pain, or hyperalgesia.

### Claim 19 (depends on 17)

The pharmaceutical composition of claim 17, wherein the pain comprises a fracture pain, a burn pain, an obstruction pain, a postherpetic pain, or a trigeminal pain.

### Claim 20 (depends on 17)

The pharmaceutical composition of claim 17, wherein the pharmaceutical composition comprises injections, suspensions, emulsions, implants, suppositories, liposomes, or lyophilizates.